Compare Google Inc (GOOG) vs Moderna, Inc. (MRNA) Price & Performance

Google IncTrade

Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Google Inc vs Moderna, Inc. — how do they compare? Google Inc trades at $356.93 (market cap $4.52T), while Moderna, Inc. trades at $63 (market cap $27.09B). The key difference: Google Inc is far larger — about 166.9× Moderna, Inc.'s market cap, and Google Inc pays a 0.24% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

	GOOG	MRNA
Market Cap	$4.52T	$27.09B
Volume	1,511,127	—
Sector	Technology	Health
52-Week High	$399.06	$81.80
52-Week Low	$183.77	$22.36
Enterprise Value	$4.49T	$23.19B
Dividend Yield	0.24%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Google Inc

Alphabet (GOOG) trades at $370.43, up 3.67% on the day, with strong bullish momentum from recent earnings beats and a consensus analyst price target of $457.50. The stock shows robust fundamentals with 2025 revenue of $402.84B, net income margin of 37.92%, and consistent cash flow growth. Technical indicators are bullish, with the current price near resistance at $374, while sentiment is positive due to Warren Buffett's recent endorsement and AI-driven growth prospects.

Outlook remains favorable with earnings growth and AI expansion as key catalysts, though regulatory risks and market volatility pose challenges. The stock offers upside potential aligned with analyst targets, supported by high institutional ownership and strong profitability metrics.

Moderna, Inc.

Moderna (MRNA) trades at $64.11, down 4.94% over 24 hours, with a bullish technical outlook but mixed fundamentals. The company reported a net loss of -$2.82B in 2025 despite beating EPS estimates in recent quarters. Recent news highlights progress in oncology trials and an EU RSV vaccine contract, fueling investor optimism about pipeline expansion beyond COVID-19 vaccines.

Outlook: Long-term growth depends on successful pipeline commercialization, but high cash burn and negative margins pose risks. Analyst consensus is cautious with a $49 price target, suggesting 23.6% downside. Investors should weigh clinical successes against persistent profitability challenges.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GOOG

Alphabet set for strong Q2 with Cloud growth and Anthropic stake boost, says Bank of AmericaProactive Investors · 7 hours agoBullish Investors can mimic Bill Ackman's portfolio via low-cost ETFs like Vanguard MGC and VUG instead of Pershing Square USA fund.24/7 Wall Street · 9 hours agoNeutral Alphabet stock rises on AI, cloud growth, and strong investor backing including Berkshire Hathaway.Tony Dante · 13 hours agoBullish View details →

MRNA

Arbutus sues Pfizer/BioNTech over LNP patents, gets $178M from Moderna, plans $230M share buybackGlobeNewsWire · 15 hours agoNeutral Moderna's Q2 report expected uneventful; key focus on COVID vaccine demand and Phase III melanoma data.Proactive Investors · 2 days agoNeutral View details →

About Google Inc

Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.